posted
Benitec MOU With CalbaTech, Inc. Stem cell storage service connected with potential Benitec HIV therapy Aug 16, 2007 11:54:00 AM
MELBOURNE, Australia, Aug 16. /PRNewswire-FirstCall/ -- Benitec Limited (ASX: BLT) has signed a Memorandum of Understanding with California-based CalbaTech, Inc. (OTC Bulletin Board: CLBE) to provide stem cell storage services for US HIV patients who may use the healthy adult (or "blood" or "hematopoietic") stem cells in future therapy.
Benitec has collaborated with City of Hope, a biomedical research and treatment center, in the development of a possible HIV therapeutic. This investigational HIV therapeutic creates the possibility that an adult (or "blood" or "hematopoietic") stem cell based therapeutic may be able to take the place of anti-retroviral medication. Early banking of adult (or "blood" or "hematopoietic") stem cells by HIV sufferers may be very prudent if a stem cell therapy is approved by the FDA after the conclusion of clinical trials.
This potential therapy surrounds a newly discovered possible way in which to fight HIV, the virus that causes AIDS, with genetically modified adult (or "blood" or "hematopoietic") stem cells. The potential therapeutic may emerge as the first to use specially engineered, HIV-fighting genes that are inserted into patients' own harvested adult (or "blood" or "hematopoietic") stem cells. After re-infusion into the patient, the new treatment may allow patients' bodies to produce HIV-resistant white blood cells indefinitely.
Benitec's MOU with CalbaTech would provide, in the short term, that Benitec would receive fees for stem cell storage performed by CalbaTech's subsidiary, TherapyStem, Inc. In the longer term, both Benitec and CalbaTech are encouraged that this potential new therapeutic will develop an effective HIV therapeutic that relies on healthy adult (or "blood" or "hematopoietic") stem cells. CalbaTech believes that, in the future, as this potential therapeutic develops, TherapyStem will be able to treat the cells that have been banked by HIV patients and send those treated cells to a patient's treating physician for re-injection. CalbaTech would pay to Benitec a fee for using the protocols developed for the treatment of the stem cells.
CalbaTech's new subsidiary, TherapyStem, Inc., has created a patent-pending., process to harvest stem cells from HIV infected individuals to be cryopreserved for future transplantation into a client for medical purposes. All other stem cell collection services exclude the collection, processing and storage of blood from individuals with HIV. As the business of TherapyStem develops, the company also believes that it will be able to collect, process and store stem cells from umbilical cords that have come from a mother that has HIV. Those cords are currently excluded from collection by cord blood companies.
Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with City of Hope in Duarte, California, is currently in Phase I trial at City of Hope. For additional information, please visit http://www.benitec.com.
Paul Knopick E & E Communications 949/707-5365
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. CalbaTech's wholly owned subsidiary LifeStem has developed a unique process to harvest stem cells in micro quantities to be cryopreserved for future transplantation into a client for medical purposes. The collection of stem cells from two different tissue sources increases the potential for treatment of more diseases. CalbaTech's new wholly-owned subsidiary, TherapyStem, Inc., with its patent pending collection service, will provide collection and processing stem cell services for individuals with infectious diseases, for possible use in potential therapeutic applications, like those created by the City of Hope, under a license agreement with Benitec, an Australian corporation.
Gene silencing
Gene silencing is about controlling the flow of genetic information. Our genome operates by sending instructions for the manufacture of proteins from DNA in the nucleus of the cell to the protein synthesizing machinery. These instructions are conveyed by messenger RNA (mRNA). In 1998 it was discovered that a certain mechanism can degrade mRNA from a specific gene. This mechanism is RNA interference. It is activated when RNA molecules occur as double-stranded pairs in the cell. Double-stranded RNA activates biochemical machinery which degrades those mRNA molecules that carry a genetic code identical to that of the double-stranded RNA. When such mRNA molecules disappear, the corresponding gene is silenced.
RNA interference is of great importance for the regulation of gene expression and can be used against viral infections. RNA interference is already being widely used in basic science as a method to study the function of genes and Benitec believes it will lead to novel therapies.
Forward-looking Statements
This press release contains forward-looking statements that reflect the Companies' current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Companies' research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE Benitec Limited; CalbaTech, Inc.
----------------------------------------------
Sue MacLeman Chief Executive Officer of Benitec Limited +61 437 211 200; or Rudi Michelson of Monsoon Communications for Benitec Limited +61 411 402 737; or Paul Knopick of E & E Communications +1-949-707-5365 for Benitec Limited and CalbaTech Inc.
-------------------- ***********************
It's all in the timing... Posts: 4303 | From: DSA | Registered: Dec 2003
| IP: Logged |
For decades, RNA molecules were dismissed as little more than drones, taking orders from DNA and converting genetic information into proteins. But a string of recent discoveries indicates that a class of RNA molecules called small RNAs operates many of the cell's controls. They can turn the tables on DNA, shutting down genes or altering their levels of expression. Science hails these electrifying discoveries, which are prompting biologists to overhaul their vision of the cell and its evolution, as 2002's Breakthrough of the Year."
J. Couzin, "Small RNAs Make Big Splash", Science 298:2296-7, 20 December2002.
Reprinted with permission from Science Volume 298, Number 5602, Issue of 20 December 2002. Illustration: Cameron Slayden. Copyright 2002 American Association for the Advancement of Science.
View our NRG Rnai Poster
Technology overview RNA Interference
Hailed the 'Breakthrough of the Year" in 2002 by Science magazine and representing a staple research tool in industry and academia, RNAi technology has gone from proof of principle in animal models to human clinical trials in less than 3 years. As an acknowledgement of the importance of this breakthrough the Nobel Prize was awarded to Fire and Mello in 2006, a mere 8 years after the publication of their seminal paper.
As a technology, several key events shaped the field of RNA interference as we know it today. The phenomenon of RNA interference was first reported in plants1 by Richard Jorgensen in 1990, although the exact mechanism was not understood until a few years later. Jorgensen's group reported the curious phenomenon that petunia pigment genes were shut down when they inserted extra copies of the genes in an attempt to deepen the purple color. In 1998, Andrew Fire and Craig Mello2 reported that dsRNAs (double stranded RNA molecules) injected into the nematode Caenorhabditis elegans silenced the corresponding genes containing complementary sequences. Benitec's Graham et al. demonstrated the universality of RNAi and invented DNA constructs to trigger the RNAi process in human and mammalian cells3 . Tuschl and colleagues4 provided a biochemical understanding of the RNAi pathway and showed that the functional units of RNAi are likely represented by dsRNAs shorter than 30 base pairs. McCaffrey et al. published the first in vivo evidence of RNA interference in adult mice5 , verifying the work of Graham et al., allowing therapeutic RNAi companies to capitalize on insights derived from the past decade of gene therapy research.
The RNAi pathway is present in every cell of virtually every multi-cellular organism and possibly evolved as an innate mechanism for cellular defense against double-stranded RNAviruses, in addition to interferon-regulated antiviral pathways. The dsRNA molecules are processed into small interfering RNA (siRNA) by a cytoplasmic enzyme called Dicer, which helps guide the siRNA to the RNA-induced silencing complex (RISC). RISC mediates sequence-specific binding to its corresponding messenger RNA (mRNA) and catalyzes the cleavage and destruction of the mRNA, leading to gene silencing. RNAi drugs are designed to exploit this natural mechanism and destroy rogue genes or viral genomes.
posted
Good news and a nice start this morning. I'd like to see some bid support fill in above .02
Posts: 134 | From: PA | Registered: Mar 2006
| IP: Logged |
posted
CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007
LAGUNA HILLS, Calif., Nov 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC BB: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on the collection and banking of adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, said today in its 10Q filing with the U.S. Securities & Exchange Commission that it anticipates to be profitable in 2007.
The addition of sales from the Stem Cell Microbank(TM) Service operated by LifeStem(TM) Inc., a CalbaTech wholly-owned subsidiary, that has developed a unique process to harvest adult stem cells in micro quantities to be cryopreserved for future transplantation into the same client for medical purposes, will play a key role in strengthening the Company's financial position, the filing said.
CalbaTech announced that sales for the third quarter dropped to $290,298, down from $322,322 in the same quarter in 2006, and nine month sales decreased to $887,959 in 2007 compared to $977,444 in the same period in 2007. The Company said a cash flow deficit was caused by its inability in the quarter to collect receivables from the National Institutes of Health, which subsequently delayed the manufacture and shipment of order, impacting revenues. The problem has been resolved.
CalbaTech said gross profits improved to $198,464 for the quarter. "We are managing our resources very carefully," said James DeOlden, CEO.
LifeStem preserves healthy cells for future medical treatments because the benefits of stem cell therapies have shown great success in the treatment of life threatening disease includingchronic heart failure and cancer, with the promise of playing prominent roles in cures for other diseases such as Parkinson's, Alzheimer's and diabetes.
The MicroBanking process, for which LifeStem has filed for US patent protection, is based on the theory that it is not necessary to harvest a quantity of stem cells capable of regenerating the entire immune system at the time of collection, but rather that these cells can be collected in micro quantities and cryo-preserved for future cellular expansion prior to reintroduction into the recipient.
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Haven't yet.....support is around .0032....
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
not enough volume yet. The wild west still asleep? lol.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
Well...back to open with a little wiggle...LMAO
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
now that's funny! we both wiggled! Bounce this pup!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
sweet...glad I wake up before the west coast does....LOL
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
wow, nice news, nice filing, and red, lol what a pos..makes no sense. looks like DOMS is the problem and slow vol out there. seems like it should be higher imo
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
the timing of the news wasnt good, the day before thanksgiving. looked like a classic frontload into news imo. i still think this has a decent chance at really running hard if/when stem cell sector heats up, and get some good news. not expecting much today b/c of holiday.
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
There is plenty more out there. Just gotta find the right companies that know wtf they're doing AND are still down at these levels lol.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
CalbaTech's Subsidiary, LifeStem, Inc., Selects Leading Physician as Chief Medical Officer IRVINE, Calif., Nov. 22 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary LifeStem, Inc., has selected Dr. Jason R. Van Tassel as its Chief Medical Officer.
Los Angeles based physician, Dr. Jason R. Van Tassel M.D., was selected to become LifeStem's Chief Medical Officer. In this new position, Dr. Van Tassel will direct all of the company's medical technologies related to its Stem Cell MicroBank service and provide advisory, consulting and technical services to the company. He will also be directly involved in the rollout of LifeStem's MicroBanking Stem Cell collection and storage service with Solana MedSpas which the company announced on November 17th.
'We're very fortunate to have Dr. Van Tassel as part of our management team,' said LifeStem President Dan Fulkerson. 'Dr. Van Tassel has been with our parent company, CalbaTech, as an advisory board member for the past year so he knows our business and as is well qualified to fill this important role,' Mr. Fulkerson added.
According to Dr. Van Tassel, the timing of his appointment was ideal. 'The stem cell market is quickly expanding and the benefits of adult stem cells as a regenerative therapy are rapidly becoming evident. With the addition of the Solana MedSpa network, I am convinced that LifeStem's MicroBank service will be an essential component to an overall stem cell therapy.'
Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, CA. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. He is an Associate Clinical Professor at UCLA in the Department of Surgery, in the Division of Otolaryngology Head and Neck Surgery. Prior to practicing medicine in Los Angeles, Dr. Van Tassel worked at Hybritech Inc., a subsidiary of Eli Lilly, where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State University.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of 'Cellular Logistics.' The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device, developed by Dr. Van Tassel, and its novel Stem Cell MicroBank service.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain 'forward looking' information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
quote: 1997 - Alpha Omega Alpha Honor Society, Georgetown University School of Medicine, Washington, DC
Impressive...like the rest of his resume...
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
CalbaTech Reports That LifeStem's Biologics License Has Been Renewed via COMTEX
November 29, 2007
LAGUNA HILLS, Calif., Nov 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on the collection and banking of adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, is pleased to announced that the California Department of Public Health has renewed LifeStem's biologics license. LifeStem is the wholly-owned subsidiary of CalbaTech in the business of collecting adult stem cells for possible therapeutic autologous future use.
"Management has worked diligently to make sure that LifeStem's biologics license was renewed. As such, LifeStem's protocols and procedures have been met the standards as set by the State of California. LifeStem has recently completed training at the state-of-the-art Youthtopia Med Spa in a suburb of Atlanta, and Youthtopia is covered under our biologics license. Anyone seeking our collection service can contact LifeStem and schedule a Stem Cell Microbank(TM) Service at Youthtopia," said James DeOlden, CEO of CalbaTech.
"We are currently in discussion with entities interested in using our services for collection in Florida, and in Northern California, and we look forward to having more locations where clients can go for our service," said Mr. DeOlden.
LifeStem(TM) Inc., a CalbaTech wholly-owned subsidiary, has developed a unique process to harvest adult stem cells in micro quantities to be cryopreserved for future transplantation into the same client for medical purposes. The benefits of stem cell therapies have shown great success in the treatment of life threatening disease including chronic heart failure and cancer, with the promise of playing prominent roles in cures for other diseases such as Parkinson's, Alzheimer's and diabetes.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, as well as providing services in the collection, processing and storage of adult stem cells.
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
Contact: Paul Knopick E & E Communications 949/707-5365 pknopick*eandecommunications.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
